Megyeri K, Dernovics Á, Al-Luhaibi ZII, Rosztóczy A. COVID-19-associated diarrhea. World J Gastroenterol 2021; 27(23): 3208-3222 [PMID: 34163106 DOI: 10.3748/wjg.v27.i23.3208]
Corresponding Author of This Article
Klara Megyeri, MD, PhD, Associate Professor, Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, Szeged 6720, Csongrad, Hungary. megyeri.klara@med.u-szeged.hu
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 21, 2021; 27(23): 3208-3222 Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3208
COVID-19-associated diarrhea
Klara Megyeri, Áron Dernovics, Zaid I I Al-Luhaibi, András Rosztóczy
Klara Megyeri, Áron Dernovics, Zaid I I Al-Luhaibi, Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged 6720, Csongrad, Hungary
András Rosztóczy, Division of Gastroenterology, Department of Internal Medicine, University of Szeged, Szeged 6720, Csongrad, Hungary
Author contributions: Megyeri K and Rosztóczy A made contributions to the concept and were involved in writing of the manuscript; Dernovics Á was involved in writing of the manuscript and creating the image; Al-Luhaibi ZII was involved in writing of the manuscript; all authors approved the final version of the article.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Klara Megyeri, MD, PhD, Associate Professor, Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, Szeged 6720, Csongrad, Hungary. megyeri.klara@med.u-szeged.hu
Received: January 28, 2021 Peer-review started: January 29, 2021 First decision: March 6, 2021 Revised: March 19, 2021 Accepted: May 20, 2021 Article in press: May 20, 2021 Published online: June 21, 2021 Processing time: 133 Days and 13.4 Hours
Core Tip
Core Tip: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates in enterocytes, triggers ionic imbalances, activates the NLRP3 inflammasome pathway, induces apoptosis, and exerts a dual effect on the autophagic process. These effects of SARS-CoV-2 lead to the development of leaky gut. Increased permeability triggers the absorption of lipopolysaccharide into the circulation, further exacerbating inflammation induced by viral infection. In addition to drugs that affect the inflammatory response and viral replication, agents targeting autophagy and apoptosis appear to be potentially suitable for the treatment of coronavirus disease 2019 (COVID-19). The fecal-oral route of SARS-CoV-2 transmission calls for strict and more consistent adherence to hygiene rules to prevent the spread of COVID-19.
